


Frovatriptan-d₃ succinate

Cat. No.:	HY-B1658BS
Molecular Formula:	C ₁₈ H ₂₀ D ₃ N ₃ O ₅
Molecular Weight:	364.41
Target:	5-HT Receptor; Isotope-Labeled Compounds
Pathway:	GPCR/G Protein; Neuronal Signaling; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	<p>Frovatriptan-d₃ (succinate) is deuterium labeled Frovatriptan (succinate). Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT_{1B} (pK₅₀ of 8.2) and 5-HT_{1D} receptor agonist. Frovatriptan succinate exhibits >10-fold selectivity for 5-HT_{1B} and 5-HT_{1D} over 5-HT_{1A}, 5-HT_{1F}, and 5-HT₇ and >1000-fold selectivity over other 5-HT, dopamine, histamine H₁, and α₁-adrenoceptor. Frovatriptan succinate has the potential for migraine research[1][2].</p>
In Vitro	<p>Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Comer MB. Et al. Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan. *Headache*. 2002 Apr;42 Suppl 2:S47-53.
- [3]. Kelman L. Review of frovatriptan in the treatment of migraine. *Neuropsychiatr Dis Treat*. 2008 Feb;4(1):49-54.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA